Institution
Aix-Marseille University
Education•Marseille, France•
About: Aix-Marseille University is a education organization based out in Marseille, France. It is known for research contribution in the topics: Population & Galaxy. The organization has 24326 authors who have published 54240 publications receiving 1455416 citations. The organization is also known as: University Aix-Marseille & université d'Aix-Marseille.
Topics: Population, Galaxy, Context (language use), Redshift, Medicine
Papers published on a yearly basis
Papers
More filters
••
TL;DR: An important role for SRPX2 is suggested in the perisylvian region critical for language and cognitive development in the human adult brain, including the rolandic area.
Abstract: The rolandic and sylvian fissures divide the human cerebral hemispheres and the adjacent areas participate in speech processing. The relationship of rolandic (sylvian) seizure disorders with speech and cognitive impairments is well known, albeit poorly understood. We have identified the Xq22 gene SRPX2 as being responsible for rolandic seizures (RSs) associated with oral and speech dyspraxia and mental retardation (MR). SRPX2 is a secreted sushi-repeat containing protein expressed in neurons of the human adult brain, including the rolandic area. The disease-causing mutation (N327S) resulted in gain-of-glycosylation of the secreted mutant protein. A second mutation (Y72S) was identified within the first sushi domain of SRPX2 in a male with RSs and bilateral perisylvian polymicrogyria and his female relatives with mild MR or unaffected carrier status. In cultured cells, both mutations were associated with altered patterns of intracellular processing, suggesting protein misfolding. In the murine brain, Srpx2 protein expression appeared in neurons at birth. The involvement of SRPX2 in these disorders suggests an important role for SRPX2 in the perisylvian region critical for language and cognitive development.
262 citations
••
Washington University in St. Louis1, Sungkyunkwan University2, Valparaiso University3, Aix-Marseille University4, Shanghai Jiao Tong University5, Chungbuk National University6, Kansai Medical University7, University of Liverpool8, Gdańsk Medical University9, Queensland University of Technology10, Bristol-Myers Squibb11
TL;DR: The addition of ipilimumab to first-line chemotherapy did not prolong OS compared with chemotherapy alone in patients with advanced squamous NSCLC and the safety profile was consistent with that observed in previous lung and melanoma studies.
Abstract: Purpose Patients with squamous non-small-cell lung cancer (NSCLC) have poor prognosis and limited treatment options. This randomized, double-blind, phase III study investigated the efficacy and safety of first-line ipilimumab or placebo plus paclitaxel and carboplatin in advanced squamous NSCLC. Patients and Methods Patients with stage IV or recurrent chemotherapy-naive squamous NSCLC were randomly assigned (1:1) to receive paclitaxel and carboplatin plus blinded ipilimumab 10 mg/kg or placebo every 3 weeks on a phased induction schedule comprising six chemotherapy cycles, with ipilimumab or placebo from cycles 3 to 6 and then, after induction treatment, ipilimumab or placebo maintenance every 12 weeks for patients with stable disease or better. The primary end point was overall survival (OS) in patients receiving at least one dose of blinded study therapy. Results Of 956 randomly assigned patients, 749 received at least one dose of blinded study therapy (chemotherapy plus ipilimumab, n = 388; chemotherapy plus placebo, n = 361). Median OS was 13.4 months for chemotherapy plus ipilimumab and 12.4 months for chemotherapy plus placebo (hazard ratio, 0.91; 95% CI, 0.77 to 1.07; P = .25). Median progression-free survival was 5.6 months for both groups (hazard ratio, 0.87; 95% CI, 0.75 to 1.01). Rates of grade 3 or 4 treatment-related adverse events (TRAEs), any-grade serious TRAEs, and TRAEs leading to discontinuation were numerically higher with chemotherapy plus ipilimumab (51%, 33%, and 28%, respectively) than with chemotherapy plus placebo (35%, 10%, and 7%, respectively). Seven treatment-related deaths occurred with chemotherapy plus ipilimumab, and one occurred with chemotherapy plus placebo. Conclusion The addition of ipilimumab to first-line chemotherapy did not prolong OS compared with chemotherapy alone in patients with advanced squamous NSCLC. The safety profile of chemotherapy plus ipilimumab was consistent with that observed in previous lung and melanoma studies. Ongoing studies are evaluating ipilimumab in combination with nivolumab in this population.
262 citations
••
TL;DR: It was found that if a vaccine against the new coronavirus became available, almost a quarter of respondents would not use it, and attitudes to this vaccine were correlated significantly with political partisanship and engagement with the political system.
261 citations
••
TL;DR: Two antibodies were generated, IPH5201 and IPH5301, targeting human membrane-associated and soluble forms of CD39 and CD73, respectively, and efficiently blocking the hydrolysis of immunogenic ATP into immunosuppressive adenosine, which promoted antitumor immunity and their combination with immune checkpoint inhibitors and chemotherapies in cancer.
261 citations
••
University of Lyon1, University of Florida2, Boston Children's Hospital3, Cincinnati Children's Hospital Medical Center4, Rambam Health Care Campus5, Spectrum Health6, University of Rochester7, University of Tennessee Health Science Center8, Royal Hospital for Sick Children9, Long Beach Memorial Medical Center10, Dresden University of Technology11, Bristol Royal Hospital for Children12, University of Verona13, Aix-Marseille University14, Case Western Reserve University15, Icahn School of Medicine at Mount Sinai16, Duke University17, Genzyme18, Millennium Pharmaceuticals19
TL;DR: In this population of infants with advanced disease, biweekly infusions with alglucosidase alfa prolonged survival and invasive ventilation-free survival and improved indices of cardiomyopathy, motor skills, and functional independence.
261 citations
Authors
Showing all 24784 results
Name | H-index | Papers | Citations |
---|---|---|---|
Didier Raoult | 173 | 3267 | 153016 |
Andrea Bocci | 172 | 2402 | 176461 |
Marc Humbert | 149 | 1184 | 100577 |
Carlo Rovelli | 146 | 1502 | 103550 |
Marc Besancon | 143 | 1799 | 106869 |
Jian Yang | 142 | 1818 | 111166 |
Josh Moss | 139 | 1019 | 89255 |
Maksym Titov | 139 | 1573 | 128335 |
Bernard Henrissat | 139 | 593 | 100002 |
R. D. Kass | 138 | 1920 | 107907 |
Stylianos E. Antonarakis | 138 | 746 | 93605 |
Jean-Paul Kneib | 138 | 805 | 89287 |
Brad Abbott | 137 | 1566 | 98604 |
Shu Li | 136 | 1001 | 78390 |
Georges Aad | 135 | 1121 | 88811 |